December 11, 2017 Bio/Pharma/CRO PR/Corporate

Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer

Basel, 11 December 2017 Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer Tecentriq and Avastin showed improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1 Data will... Read more

December 11, 2017 Bio/Pharma/CRO PR/Corporate

Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer

Basel, 11 December 2017 Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer Tecentriq and Avastin showed improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1 Data will... Read more

December 10, 2017 Bio/Pharma/CRO PR/Corporate

Phase II data showed Roche’s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma

Basel, 10 December 2017 Phase II data showed Roche’s investigational polatuzumab vedotin plus bendamustine and MabThera/Rituxan (BR) increased complete response rates compared to BR alone in previously treated aggressive lymphoma Polatuzumab vedotin combination demonstrated improvements across multiple efficacy measures compared to BR alone in relapsed or refractory diffuse large B-cell lymphoma These data led to... Read more

December 9, 2017 Uncategorized

Roche’s Hemlibra continued to substantially reduce bleeds in people with haemophilia A with inhibitors

Basel, 09 December 2017 Roche’s Hemlibra continued to substantially reduce bleeds in people with haemophilia A with inhibitors Newly approved Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents as prophylaxis or on-demand Nearly 95% of children who received Hemlibra experienced zero treated bleeds Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that... Read more

December 7, 2017 Bio/Pharma/CRO

Roche’s Hemlibra every four weeks controlled bleeds in phase III study in haemophilia A

Basel, 07 December 2017 Roche’s Hemlibra every four weeks controlled bleeds in phase III study in haemophilia A Less frequent administration of Hemlibra demonstrated clinically meaningful bleed control Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive interim results from the phase III HAVEN 4 study evaluating Hemlibra® (emicizumab) prophylaxis dosed once every four weeks... Read more

December 7, 2017 Bio/Pharma/CRO PR/Corporate

Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer

Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer First Phase III combination trial of a cancer immunotherapy to show improvement in progression-free survival as an initial treatment... Read more

December 5, 2017 Acad, Gov/Utilities Clinical Research/Diagn.

TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) FDA partial clinical hold lifted

Basel, 05 December 2017 TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) FDA partial clinical hold lifted Roche (SIX: RO, ROG; OTCQX: RHHBY): today announced that following close consultation and agreement on study modifications with the U.S. Food and Drug Administration (FDA), the partial clinical holds placed on the Phase Ib and Phase Ib/II studies evaluating TECENTRIQ... Read more

December 4, 2017 Acad, Gov/Utilities Clinical Research/Diagn.

FDA approves Foundation Medicine’s FoundationOne CDx, the first pan-tumour comprehensive genomic profiling assay incorporating a broad range of companion diagnostics

Basel, 04 December 2017 FDA approves Foundation Medicine’s FoundationOne CDx, the first pan-tumour comprehensive genomic profiling assay incorporating a broad range of companion diagnostics Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved FoundationOne CDx™, Foundation Medicine’s comprehensive companion diagnostic assay for personalised oncology care1. FoundationOne... Read more

November 20, 2017 Bio/Pharma/CRO

Roche’s Hemlibra significantly reduced bleeds in phase III study in haemophilia A

Basel, 20 November 2017 Roche’s Hemlibra significantly reduced bleeds in phase III study in haemophilia A HAVEN 3 study met primary endpoint and key secondary endpoints Intra-patient comparison demonstrated superiority of Hemlibra prophylaxis compared to prior factor VIII prophylaxis Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the phase III HAVEN 3... Read more